Total Events and Net Clinical Benefit of Reveroxaban in Combination with Aspirin in Patients with Chronic Coronary Artery Disease and Peripheral Artery Disease: The COMPASS Study
The COMPASS trial showed that low-dose rivaroxaban plus aspirin significantly reduced first-time and total cardiovascular events compared with aspirin alone, with a 20% higher net clinical benefit, Dr. Kelley R. H. Branch and and colleagues of the University of Washington, Washington, USA, reported in the April issue of the American Heart Journal.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
